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C15H16N2O4 
 
Methyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxooctahydro pyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +140º (c 0.5, CHCl3, >99% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C17H20N2O4 
 
Isopropyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxoocta hydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +63º (c 1, CHCl3, 87% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C16H18N2O4 
 
Ethyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxooctahydro pyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +74º  (c 1, CHCl3, 92% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C19H18N2O4 
 
Methyl (1S,3R,3aS,6aR)-5-methyl-3-(2-naphthyl)-4,6-dioxoocta hydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +109.4 (c 1, CHCl3, >99% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C18H22N2O4 
 
tert-Butyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxoocta hydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +33.9º (c 0.8, CHCl3, 91% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C16H18N2O4  
Methyl (1S,3R,3aS,6aR)-5-methyl-4,6-dioxo-3-o-tolyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +50.8º (c 0.6, CHCl3,70 % ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C15H15 ClN2O4 
 
Methyl (1S,3R,3aS,6aR)-3-(2-chlorophenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +27.1 (c  1, CHCl3, >99% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
 
 
 
5 
 
 
J. Mancebo-Aracil , M. Martín-Rodríguez,  C. Nájera, J. M. 
Sansano*, P. R. R. Costa, E. Crizanto de Lima, A. G. Dias 
 
N
H
N
CO2Me
OO
N  
 
C14H15N3O4 
 
Methyl (1S,3R,3aS,6aR)-3-(3-pyridyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +8º (c 0.5, CHCl3, 40% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C16H18N2O4 
 
Methyl (1S,3R,3aS,6aR)-5-methyl-3-(4-methylphenyl)-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +89º (c 0.4, CHCl3, 99% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C15H15ClN2O4 
 
Methyl (1S,3R,3aS,6aR)-3-(4-chlorophenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +39º (c 0.8, CHCl3, 94% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C13H14N2O4S 
 
Methyl (1S,3R,3aS,6aR)-5-methyl-4,6-dioxo-3-(2-thienyl)octahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +48º (c 0.6, CHCl3, 93% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C15H18N2O4 
 
Methyl (1S,3R,3aS,6aR)-5-ethyl-4,6-dioxo-3-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +58.7º (c 0.5, CHCl3, 99% ee from HPLC)  
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C15H16N2O4 
 
Methyl (1S,3R,3aS,6aR)-4,6-dioxo-3,5-diphenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  + 40.2º (c  0.5, CHCl3, 82% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
 
 
 
J. Mancebo-Aracil , M. Martín-Rodríguez,  C. Nájera, J. M. 
Sansano*, P. R. R. Costa, E. Crizanto de Lima, A. G. Dias 
 
N
H
N
CO2Me
Ph
OO
 
 
C16H18N2O4 
 
Methyl (1S,3R,3aS,6aR)-1,5-dimethyl-4,6-dioxo-3-phenyloctahydro pyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +108.6 (c 1, CHCl3, 99% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C21H20N2O4 
 
Methyl (1S,3R,3aS,6aR)-5-benzyl-4,6-dioxo-3-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +69.4º (c 1, CHCl3, 98% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C17H22N2O4S 
 
Methyl (1S,3R,3aS,6aR)-1-isobutyl-5-methyl-4,6-dioxo-3-(2-thienyl)octahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +24.7º (c  1, CHCl3, 91% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C22H22N2O4 
 
Methyl (1S,3R,3aS,6aR)-1-benzyl-5-methyl-4,6-dioxo-3-phenyl octahydropyrrolo[3,4-c]pyrrole-1-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = -75.8 (c 0.8, CHCl3, 99% ee from HPLC) 
 
Absolute configuration: (1S,3R,3aS,6aR) 
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C28H25NO6S2 
 
Methyl (2R,3R,4R,5S)-5-(naphth-2-yl)-3,4-bis(phenylsulfonyl) pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +17.1º (c 0.5, CHCl3, 92% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C24H23NO6S2 
 
Methyl (2R,3R,4R,5S)-5-phenyl-3,4-bis(phenylsulfonyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +1.2º (c 1, CHCl3, 90% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C29H25NO6S2 
 
Methyl (2R,3R,4R,5S)-2-methyl-5-(naphth-2-yl)-3,4-bis(phenyl sulfonyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +5.2º (c 1, CHCl3, 24% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C25H25NO6S2 
 
Methyl (2R,3R,4R,5S)-3,4-bis(phenylsulfonyl)-5-(o-tolyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +1.7º (c 0.8, CHCl3, 18% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C25H25NO7S2 
 
Methyl (2R,3R,4R,5S)-5-(4-methoxyphenyl)-3,4-bis(phenylsulfonyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  -4.5º (c 1, CHCl3, % ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
 
 
 
J. Mancebo-Aracil , M. Martín-Rodríguez,  C. Nájera, J. M. 
Sansano*, P. R. R. Costa, E. Crizanto de Lima, A. G. Dias 
 
 
N
H
CO2Me
PhO2S SO2Ph
 
 
C25H25NO6S2 
 
Methyl (2R,3R,4R,5S)-3,4-bis(phenylsulfonyl)-5-(p-tolyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +2.3º (c 1, CHCl3, 88% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C24H22ClNO6S2 
 
Methyl (2R,3R,4R,5S)-5-(4-chlorophenyl)-3,4-bis(phenylsulfonyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +91.6º (c 1, CHCl3, 45% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C26H26ClNO6S2 
 
Isopropyl (2R,3R,4R,5S)-5-(4-chlorophenyl)-3,4-bis(phenylsulfonyl) pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +37.0º (c 0.7, CHCl3, 40% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C22H20NO6S3 
 
Methyl (2R,3R,4R,5S)-2-isobutyl-3,4-bis(phenylsulfonyl)-5-(thien-2-yl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +7.1º (c 1, CHCl3, 70% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C23H22N2O6S2 
 
Methyl (2R,3R,4R,5S)-3,4-bis(phenylsulfonyl)-5-(pyrid-3-yl) pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  -63.9º (c 1.2, CH2Cl2, 93% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
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C40H46N2O9S3Si 
 
Methyl (2R,3R,4R,5S)- 5-{3-[2-((tert-butyldimethylsilyl)oxy)ethyl]-1-(phenylsulfonyl)-1H-indol-2-yl}-3,4-
bis(phenylsulfonyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = -4.5º (c 1, CHCl3, 12% ee from HPLC) 
 
Absolute configuration: (2R,3S,4S,5S) 
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C30H33NO10S2 
 
Methyl (2R,3S,4S,5S)-5-[2-(2-acetoxyethyl)-4,5-dimethoxyphenyl]-3,4-bis(phenylsulfonyl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = -25.3º (c 1, CHCl3, 50% ee from HPLC) 
 
Absolute configuration (2R,3S,4S,5S) 
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C12H15NO2 
 
Methyl (2S,5R)-5-phenylpyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 = +19.0 (c 1, CH2Cl2, 90% ee from HPLC) 
 
Absolute configuration: (2S,5R) 
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C21H19N2O6S3 
 
Methyl (2R,3R,4R,5S)-2-isobutyl-3,4-bis(phenylsulfonyl)-5-(thiazol-2-yl)pyrrolidine-2-carboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +4.1º (c 1, CH2Cl2, 10% ee from HPLC) 
 
Absolute configuration: (2R,3R,4R,5S) 
 
 
 
11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J. Mancebo-Aracil , M. Martín-Rodríguez,  C. Nájera, J. M. 
Sansano*, P. R. R. Costa, E. Crizanto de Lima, A. G. Dias 
 
N
H
CO2Me
tBuO2C
N
S  
 
C18H28N2O4S 
 
tert-Butyl methyl (2S,4S,5R)-2-isobutyl-5-(thiazol-2-yl)pyrrolidine-2,4-dicarboxylate 
 
 
 
Source of chirality: (Sa)-Binap 
 
[α]D20 =  +38.0º(c 1, CH2Cl2, 88% ee from HPLC) 
 
Absolute configuration: (2S,4S,5R) 
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1. Introduction 
Privileged chiral ligands1 are the most efficient 
enantiomerically pure molecules, incorporating few core 
structures, which are taking as reference for every chemist 
working in the field of asymmetric catalysis. Binap is a clear 
cut example of this concept, which has been used together 
with ruthenium, rhodium, and palladium in many organic 
enantioselective transformations.1 This chiral diphosphane 
was also tested in the catalytic enantioselective 1,3-dipolar 
cycloaddition2 (1,3-DC) of azomethine ylides (derived from 
imino esters) and electrophilic alkenes.3 In the first 
substoichiometric catalytic enantioselective 1,3-DC of 
azomethine ylides reported by Zhang et al.,4  the combination 
of (S)-Binap-AgOAc (3 mol%) showed low ee when dipoles 
derived from imino esters and dimethyl maleate (up to 13% 
ee). The change of the counterion of the complex by our group 
was critical for the reaction success. In this way, (S)-Binap-
AgClO4 1, a very stable and recyclable complex, resulted to be 
very appropriate in the 1,3-DC of imino esters and maleimides 
(up to >99% ee).5 Apart from silver(I), copper(I)6 and (II),7 
and gold(I)8,9,10 chiral Binap complexes have been studied as 
catalysts in analogous 1,3-DCs using several dipolarophiles. 
Reluctance of chemical companies to perchlorate salts 
moved us to search another poorly coordinated anion in order 
to ensure or even improve the results obtained from (S)-Binap-
AgClO4 complex. Computational studies of this asynchronous 
transformation also revealed that in the transition state, 
responsible of the enantiodiscrimination, the perchlorate anion 
was weakly bonded to the central metal (2.41 Å).5b Based on 
this data, we thought that weakly coordinating 
hexafluoroantimonate anion would be an alternative to 
perchlorate as catalyst of this particular cycloaddition. An 
identical semi-empirical model to the already described, but 
incorporating SbF6- instead of ClO4-, shown a longer distance 
(2.46 Å) between silver central atom and its counterion.11 In 
this article, we will search how important this small distance 
difference is during the enantioselective catalyzed 1,3-DC 
between imino esters and electron-deficient alkenes, and the 
scope of  (S)-Binap-AgSbF6 catalyst 2 vs. other Binap 
complexes formed with different silver(I) salts.12 
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2. Discussion 
2.1. Optimization of the reaction conditions. 
The selected model reaction between methyl 
benzylideneiminoglycinate 3aa and N-methylmaleimide 
(NMM) 4a was performed in toluene at room temperature 
using 5 mol % of (S)-Binap  and 5 mol% of AgI salt as catalyst 
precursor (Scheme 1 and Table 1). The reaction run with 
equimolar amount of both (Sa)-Binap and several oxygenated 
silver(I) salts with a weak coordinating anion, such as AgOAc, 
AgOTfa (Tfa = trifluoroacetate), AgOTf (Tf = 
trifluoromethanesulfonate) AgNO3, and AgBF4, (5 mol%) 
were compared. When AgOAc was used excellent results of 
the compound 5aa were obtained by using triethylamine rather 
than DABCO (Table 1, entries 1 and 2), but the crude reaction 
product was not very clean. Silver trifluoroacetate also yields 
an excellent result of cycloadduct 5aa, but again the reaction 
crude product was slightly unpurified (1H NMR) (Table 1, 
entry 3). This chiral catalyst can work as an internal base, the 
trifluoroacetate anion being the most effective (Table 1, entry 
4). In this case, the enantioselection was excellent, the reaction 
slightly slower and a few impurities in the crude product were 
detected. The bifunctional behavior of acetate derived catalyst 
was not as effective as Tfa complex did, affording lower yield 
of the cycloadduct 5aa. Silver triflate afforded excellent 
enantioselection (99% ee) but with a higher amount of the exo-
diastereoisomer (Table 1, entry 5). The rest of the silver salts 
described in Table 1 were not able to promote the 1,3-DC in 
the absence of an external base. AgBF4 or AgNO3 catalyzed 
reactions affording lower chemical yields, diastereo- and 
enantioselections (Table 1, entries 6 and 7). 
Using AgSbF6 and Et3N as base, enantiomerically 
enriched cycloadduct 5aa (>99% ee) was isolated in very good 
yield (90%) and with an excellent endo-selectivity.13 This 
result, and the obtained when the reaction was performed with 
AgClO4, were almost identical (Table 1, entry 8). Other 
solvents, such as Et2O, DCM, THF, and MeCN, were tested 
but neither the purity nor diastereo-/enantioselection of the 
final product 5aa were improved. The 5 mol% catalyst loading 
was the most appropriate because the reaction became slower 
when a 3 mol% charge was placed instead (Table 1, entry 9). 
Bases like 1,4-diazabicyclo[2.2.2]octane (DABCO) or 
diazabicyclo[5.4.0]undec-7-ene (DBU) were evaluated in this 
reaction affording lower enantioselections with some 
unidentified products in the crude mixture (Table 1, entries 10, 
and 11). However, the reaction run with N,N-
diisopropylethylamine (DIPEA) was completely equivalent to 
the reaction done with triethylamine (Table 1, compare entries 
8 and 10). Different stoichiometry to 1:1 (Sa)-Binap:silver salt, 
such as 2:1 or 1:2, afforded lower enantioselections and larger 
amounts of the exo-diastereoisomer in both situations (Table 1, 
entries 13 and 14).  
 So, the reaction involving silver hexafluoroantimonate in 
the presence of a tiny amount of thiethylamine ensures a good 
chemical yield, an excellent enantioselection (>99%) and a 
very clean material that did not require any additional 
purification. 
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Scheme 1.  Reagents and conditions: i) (Sa)-Binap (5 mol%), AgI salt (5 
mol%), base (5 mol%), toluene, 25 ºC, 16 h. 
Table 1. Optimization of the reaction of imino esters 3aa with NMM (4a). 
   Product 5aaa 
 AgI salt Base  Yield 
(%)b 
endo:exoc ee (%)d 
1 AgOAc Et3N 89 >98:2 99e 
2 AgOAc DABCO 85 >95:5 94 
3 AgOTfa Et3N 89 >98:2 99e 
4 AgOTfa ___ 78 >98:2 99e 
5 AgOTf Et3N 88 90:10 99 
6 AgNO3 Et3N 65 85:11 67  
7 AgBF4 Et3N 77 89:11 72 
8 AgSbF6 Et3N 90 (89) >98:2 (>98:2) >99 (>99) 
9 AgSbF6 f Et3N 78 (80) >98:2 (>98:2) >99 (>99) 
10 AgSbF6 DIPEA 89 (89) >98:2 (>98:2) >99 (>99) 
11 AgSbF6 DABCO 87 (88) >90:10 
(>90:10) 
94  (92)e 
12 AgSbF6 DBU 87 (80) >90:10 
(>90:10) 
90  (91)e 
13 AgSbF6g Et3N 90 (90) 90:10 (90:10) 96 (98)e 
14 AgSbF6h Et3N 90 (91) >98:2 (>98:2) 56 (<50)e 
a Conversions were higher than 95% (determined by 1H NMR 
spectroscopy of the crude product).  
b Isolated yield after recrystallization. The yields of the analogous reaction 
performed with AgClO4 are given in parenthesis.5 
c Determined by 1H NMR spectroscopy of the crude product. 
d Determined by HPLC of the crude product employing chiral columns 
(Daicel Chiralpak AS). The ee of the analogous reaction performed with 
AgClO4 are given in parenthesis.5 Identical ee was determined for the 
purified product in both reaction sets. 
e Some unidentified  impurities were detected  in the crude product.  
f Reaction performed with a 3 mol% of the catalyst. 
g Reaction performed with 2 equiv. of Binap and 1 equiv. of AgI salt. 
h Reaction performed with 1 equiv. of Binap and  2 equiv. of AgI salt. 
 
 
2.2. Characterization of the catalytic species. 
The reaction was also carried out with the isolated complex 
formed by the addition of equimolar amounts (S)-Binap and 
AgSbF6, obtaining almost identical results to those described 
in entry 8 of the Table 1. However this AgSbF6 derived 
complex became darker upon standing being much more 
unstable than the identical complex generated by AgClO4. So, 
the in situ generation of the catalytic complex, avoiding the 
light exposure during the whole process was preferred for all 
the transformations described in the text. 
The presumed catalytic monomeric species in solution are 
identical to those the reported previously with triflate14 (Figure 
2) or perchlorate anions.5b Complexes formed from silver 
triflate and (R) or (S)-Binap, were isolated at different 
temperatures and further characterized by X-ray diffraction 
analysis by Yamamoto’s group. These studies revealed that 
mixture of structures 6-8 are in equilibrium, and at room 
temperature, being the 1:1 complex 7 the most abundant 
system (Figure 2). 
The 1:1 (R)- or (S)-Binap and AgSbF6 complexes were 
characterized by ESI-MS experiments and 31P NMR. ESI-MS 
reveled  a M++1 signal at 730, and 732 corresponding to the 
monomeric Binap-AgI complex (Sa)-2 and a tiny one at 1352 
and 1354 corresponding to the 2:1 Binap:AgSbF6 (similar to 
complex 6). The 31P NMR (CDCl3) spectra of 1:1 (R)- or (S)-
Binap and AgSbF6 (10% aqueous polyphosphoric acid as 
internal reference) afforded signals at 15.31 ppm and 15.45 
ppm (2d, J = 242 Hz) (15.26, and 15.35 ppm for Binap-
AgClO4 complex).  
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Figure 1. [(R)-Binap]AgOTf complexes and catalyst-dipole complex 9. 
 
 
Calculations performed with Binap-AgClO4 model, which 
are comparable with Binap-AgSbF6 model, supported that 
NMM was the best dipolarophile due to the coordination of 
the nitrogen atom to the metal centre. The TS responsible of 
the enantiodiscrimination is, as expected, quite asynchronous. 
On it a very important steric interaction between one of the 
phenyl groups of the phosphine moiety of chiral ligand and the 
dipolarophile can be considered crucial for explaining the 
experimental findings and providing a rationale for the 
observed excellent asymmetric induction. 
 
15 
 
2.3. General scope of the (Sa)-Binap-AgSbF6 catalyzed 1,3-
DC. 
The optimized reaction conditions were employed in the 
diastereo- and enantioselective transformation of several 
azomethine ylides, generated from the corresponding methyl 
arylideneiminoglycinates 3, and maleimides into the 
corresponding cycloadducts endo-5.  Reactions employing a 5 
mol% of an equimolar mixture of (S)-Binap and AgSbF6 in 
the presence of toluene as solvent and a catalytic amount of 
triethylamine (5 mol%) were directly compared with the 
analogous results obtained with (S)-Binap-AgClO4 complex5 
(Scheme 2, and Table 2).  
In general, we can observe that isolated chemical yields of 
compounds 5 are identical to each other. For example, for Ar = 
Ph, 2-naphthyl, and 2-thienyl, there was no difference in terms 
of enantioselection between both catalytic complexes (Table 2, 
entries 1, 6 and 12). These three entries were also repeated 
employing (S)-Binap-AgTfa with no added base, finding 
similar enantioselections and lower chemical yields of slightly 
unpurified cycloadducts endo-5 (not shown in Table 2). When 
the reaction was performed with (R)-Binap the corresponding 
enantiomer of endo-5aa was isolated in good yield and 
excellent enantioselectivity (Table 2, entry 2). A modification 
of the alkyl moiety of the ester group produced a drop of the 
diastereoselection, higher when the tert-butyl ester was tested 
(Table 2, entries 3-5). In all these cases the enantioselectivity 
was lower than the obtained one for the methyl ester. For 
substituted aromatic imino esters, the enantioselection was 
always higher when AgSbF6 was selected as co-catalyst, 
except when o-tolyl derivative 3ca was used (Table 2, entries 
7-10). Heteroaromatic groups, attached to the 1,3-dipole 
precursor, influenced the reaction course. Whereas 2-thienyl 
derivative furnished 5ha with very good enantioselection, 3-
pyridyl derivative 3ga is not suitable for this particular 
transformation (Table 2, entries 11 and 12). Presumably, the 
basic character of the nitrogenated heterocycle promoted the 
non-asymmetric process.  
The absolute configuration of these products 5, as well as 
all compounds described along the text, was determined by 
comparison of known data reported in the literature for 
identical molecules.  
When different N-substituted maleimides were compared, it 
was detected that N-ethylmaleimide (NEM) did not represent 
any difference with respect to those results obtained in the (S)-
Binap-AgClO4. However, the reaction carried out with N-
phenylmaleimide (NPM) was much more enantioselective in 
the presence of (S)-Binap-AgSbF6 complex than that obtained 
with perchlorate derived chiral complex (82% ee, vs. 62% ee). 
Computational calculations justified this difference because of 
the existence of steric hindrance between the phenyl group of 
the NPM and the Binap-AgClO4 catalyst.5b Less coordinating 
anion in the catalyst Binap-AgSbF6 released the steric 
congestion of the transition state. In the examples run with N-
benzylmaleimide the difference of ee in product endo-8 was 
not so important (Scheme 3). Products endo-6, endo-7, and 
endo-8 were isolated as more than 98:2 endo:exo ratio 
independently of the chiral catalyst employed.  
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Scheme 2.  Reagents and conditions: i) (Sa)-Binap (5 mol%), AgI salt (5 
mol%), Et3N (5 mol%), toluene, 25 ºC, 16 h. 
 
 
 
Table 2. 1.3-DC of iminoglycinates 3 and NMM 4a. 
    Product endo-5 
Entry Nº Ar R1 No. Yield (%)a,b endo:exob,c eeendo (%)b,d 
1 3aa Ph Me 5aa 90 (90) >98:2 >99 (>99) 
2 3aae Ph Me ent-5aa 90 (90) >98:2 >99 (>99) 
3 3ab Ph Et 5ab 81 (78) 95:5 (90:10) 92 (91) 
4 3ac Ph Pri 5ac 80 (81) 90:10 87 (72) 
5 3ad Ph But 5ad 81 (79) 80:20 (75:25) 91 (92) 
6 3ba 2-naphthyl Me 5ba 89 (80) >98:2 >99 (>99) 
7 3ca 2-CH3C6H4 Me 5ca 85 (85) >98:2 70 (75) 
8 3da 2-ClC6H4 f Me 5da 85 (88)  >98:2 >99 (85) 
9 3ea 4-CH3C6H4 Me 5ea 85 (85) >98:2 99 (80) 
10 3fa 4-ClC6H4 Me 5fa 84 (87) >98:2 94 (65) 
11 3ga 3-Pyridyl Me 5ga 77 (81) 80:20 40 (10) 
16 
 
12 3ha 2-thienyl Me 5ha 84 (87) >98:2 (90:10) 93 (92) 
 
a Isolated yield after flash chromatography. 
b In brackets the result obtained previously with (S)-Binap-AgClO4 complex.5 
c Determined by chiral 1H NMR of the crude product.  
d Determined by HPLC of the crude product using chiral columns. Identical ee was determined after purification of 5. 
e Reaction performed with (R)-Binap-AgSbF6. 
f Reaction performed at −20 ºC. 
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Scheme 3.  Reagents and conditions: i) (Sa)-Binap (5 mol%), AgI salt (5 
mol%), Et3N (5 mol%), toluene, 25 ºC, 16 h. 
 
The effect of the α-substitution in the 1,3-dipole precursor 
was next evaluated. Alanine, leucine and phenylalaninates 9 
were allowed to react with NMM under the typical reaction 
conditions taking 48 h to reach complete conversions (Scheme 
4). Cycloadducts endo-10 were obtained in good yields when 
both chiral catalysts were used, but the enantioselectivity 
achieved by (Sa)-Binap-AgSbF6 was noticeably higher. This is 
another evidence of the facility of the hexafluoroantimonate 
salt to perform cycloadditions with sterically hindered 
components.  
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Scheme 4.  Reagents and conditions: i) (Sa)-Binap (5 mol%), AgI salt (5 
mol%), Et3N (5 mol%), toluene, 25 ºC, 48 h. 
 
 
We have also found that dipolarophiles such as alkyl 
acrylates, dialkyl fumarates, dimethyl maleate and acrylonitrile 
exhibited exactly identical behavior with both silver salts, that 
means very low enantioselections and good chemical yields 
were obtained. Also more polar solvents, such as acetone, 
acetonitrile, diethyl ether, ethanol, and water were essayed but 
cycloaddition was not completed at all and the crude reaction 
mixtures were notably impurified. When small amounts of 
cycloadducts were isolated the enantioselections were almost 
zero. 
However, big differences were detected when 1,2-
bis(phenylsulfonyl)ethylene was employed as low-LUMO 
alkene (Scheme 5 and Table 3). Despite toluene was used as 
the selected solvent, the reactions run in THF were also 
compared because it was observed a very clean reaction 
mixture, and crude products endo-12 did not require additional 
purification. The reaction performed with (S)-Binap-AgClO4 
never improved the results generated by intermediacy of (S)-
Binap-AgSbF6. Phenyl- and 2-naphthyl substituents bonded to 
the imino group afforded high enantioselections of the product 
12aaa and 12baa, respectively (Table 3, entries 1-4). The 
effect of the methyl group in the azomethine ylide caused 
lower enantioselections in final products 12bba (Table 3, 
entries 5 and 6). The introduction of a substituent in the 
arylidene moiety of the imino ester was not very profitable 
because the ee of cycloadducts were very low, except in the 
case of para-methyl substituted derivative (Table 3, entries 7-
17 
 
14). The presence of an isopropyl ester instead of the methyl 
one also gave a disappointing enantioselection of heterocycle 
12fab (Table 3, entries 15 and 16). 3-Pyridyl group was the 
most appropriate heterocycle (Table 3, entries 17 and 18) 
because 2-thienyl and 2-thiazolyl imino esters, present in 
antiviral agents, did not afford very high enantioselections in 
spite of producing an excellent yield (Table 3, entries 19-22). 
Sterically hindered imino esters furnished lower endo:exo ratio 
such as occurred in ortho-substituted arylinenes, isopropyl 
esters, and α-branched amino acid derivatives (alanine and 
leucine), and far more when (S)-Binap-AgClO4 was employed 
(Table 3, entries 5-8, 15, 16, and 19-22). 
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Scheme 5.  Reagents and conditions: i) (Sa)-Binap (5 mol%), AgI salt (5 
mol%), Et3N (5 mol%), toluene or THF, 25 ºC, 48 h. 
 
 
Table 3. 1.3-DC of iminoglycinates 9 and disulfone 11. 
      Product endo-12 
Entry  Ar R1 R2 Solvent No. Yield. (%)a,b endo:exob,c eeendo (%)b,d 
1  Ph H Me PhMe 12aaa 81 (80) >98:2 90 (88) 
2  Ph H Me THF 12aaa 82  >98:2 90  
3  2-Naphthyl H Me PhMe 12baa 91e (88) >98:2 92 (80) 
4  2-Naphthyl H Me THF 12baa 90  >98:2 80  
5  2-Naphthyl Me Me PhMe 12bba 95e (82) 90:10 24 (10) 
6  2-Naphthyl Me Me THF 12bba 91e  90:10 12  
7  2-CH3C6H4 H Me PhMe 12caa 63 (79) 90:10 18 (16) 
8  2-CH3C6H4 H Me THF 12caa 68 90:10 6 
9  4-CH3C6H4 H Me PhMe 12daa 91e  (78) >98:2 88 (28) 
10  4-CH3C6H4 H Me PhMe 12daa 78 >98:2 82 
11  4-MeOC6H4 H Me PhMe 12eaa 58 (60) >98:2 38 (28) 
12  4-MeOC6H4 H Me THF 12eaa 78 >98:2 12 
13  4-ClC6H4 H Me PhMe 12faa 81 (85) >98:2 45 (27) 
14  4-ClC6H4 H Me THF 12faa 79 >98:2 42 
15  4-ClC6H4 H Pri PhMe 12fab 64 (71) 80:20 40 (30) 
16  4-ClC6H4 H Pri THF 12fab 93e 80:20 30 
17  3-Pyridyl H Me PhMe 12gaa 83 (82) >98:2 93 (78) 
18  3-Pyridyl H Me THF 12gaa 92e >98:2 90 
19  2-Thienyl Bui Me PhMe 12hca 92 (<50) 90:10 (75:25) 70 (12) 
20  2-Thienyl Bui Me PhMe 12hca 95e 90:10 (75:25) 58 
21  2-Thiazolyl Bui Me PhMe 12ica 92e (<50) 90:10 (75:25) 10 (8) 
22  2-Thiazolyl Bui Me PhMe 12ica 93e  90:10 (75:25) 4 
 
a Isolated yield after flash chromatography. 
b In brackets the result obtained previously with (S)-Binap-AgClO4 complex. 
c Determined by chiral 1H NMR of the crude product.  
d Determined by HPLC of the crude product using chiral columns. Identical ee was determined after purification of 12. 
e No additional purification was required. 
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Multicomponent reactions were attempted using the best result 
depicted in Tables 2 and 3. Thus, benzaldehyde/NMM 4a or 3-
pyridinecarbaldehyde/disulfone 11, glycine methyl ester 
hydrochloride, triethylamine (1.05 equiv), (S)-Binap-AgSbF6 (5 
mol%), were put together in toluene and the resulting mixture 
was allowed to react at 25 ºC for 48 h. The results obtained for 
compound endo-5aa or endo-12gaa were impressive (88% yield, 
>99% ee, or 86% yield, 98% ee, respectively, Scheme 6). 
However, analogous reactions carried out in the presence of (S)-
Binap-AgClO4 complex failed. Although very activated 
aminomalonates have been involved as one of the three 
components of the enantioselective organocatalyzed 1,3-DC, this 
was the first occasion that a three-component transformation is 
enantioselectively performed in the presence of a chiral Lewis 
acid. Disappointingly, the employment of other substrates with 
these two dipolarophiles did not afford neither the expected 
enantioselections nor even good chemical yields. The 
introduction of the free α-amino ester instead of the 
corresponding hydrochloride did not represent any improvement. 
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Scheme 6. Reagents and conditions: i) (Sa)-Binap (5 mol%), AgSbF6 (5 
mol%), Et3N (5 mol%), toluene, 25 ºC, 16 h. ii) (Sa)-Binap (5 mol%), 
AgSbF6 (5 mol%), Et3N (5 mol%), toluene, 25 ºC, 48 h. 
 
 
2.4. Applications of (Sa)-Binap-AgX  catalyzed 1,3-DC. 
As masked acetylene equivalent, disulfone 11 has been used 
in this 1,3-DC for the preparation of very interesting Schramm’s 
C-azanucleoside,15 which is a promising trypanosomal 
nucleoside hydrolase inhibitor. In this work the enantioselective 
synthesis of the exo-cycloadduct (type 12) was the key step of the 
total process, and next the methoxycarbonyl group was reduced 
with lithium aluminum hydride (LAH) followed by the complete 
desulfonylation with sodium amalgam. In our case, when the 
enantiomerically enriched endo-12aaa was allowed to undergo 
this double reduction protocol (LAH plus amalgam) a very 
complex reaction mixture was obtained, pyrrole being the major 
product observed. In spite of several conditions essayed the 
behavior of the endo-diastereoisomer is very different to the exo 
one, even in terms of stability upon flash chromatography. 
The synthesis of 5-substituted prolines can be another 
interesting application because gives access to biologically active 
compounds, such as nonpeptide cholecystokinin antagonist (+)-
RP 66803 13.16 The 5-phenylprolinate fragment was prepared 
according to the route described in Scheme 7. Isomers 14 and 15 
were obtained after desulfonylation with sodium amalgam (10%) 
and the crude mixture, without purification, was submitted to 
hydrogenation with Pt/C (10%). The enantiomeric excesses of 
both prolinates remained unaltered with respect to the starting 
disulfonylated heterocycle ones. The overall yield of 16 was 47 
(Scheme 7). This low yield could be justified by the formation of 
significant amounts of pyrrole derivative after the 
desulfonylation step.  
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Scheme 7. Reagents and conditions: i) Na(Hg), 10%, MeOH/THF (3/1), from 
0 to 25 ºC, 1h. ii) Pt/C (10%), H2 (1 atm), MeOH, 48 h, 25 ºC. 
 
(R)-(+)-Crispine A 17 and (R)-(+)-harmicine 18 are naturally 
occurring molecules employing in traditional medicine. The 
anticancer properties of the former and the anti-leishmaniasis 
effects of the latter have attracted the attention of many 
scientists.17,18 Following the approach of Coldham’s group, 
inspired in a 1,3-DC using disulfone 11 (Scheme 8),19 new 
starting -suitably protected- aromatic precursors 19 and 20 were 
prepared.   
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Scheme 8. Retrosynthetic analysis of natural products 19 and 20. 
 
The reaction of the imine 21(obtained from the corresponding 
aldehyde20 and methyl glycinate) and disulfone 11 was 
accomplished at 20-25 ºC in toluene as solvent and a 10 mol% of 
catalyst loading (formed by chiral Binap and a silver salt) and in 
the presence of a base or not (Scheme 9 and Table 4). AgSbF6, 
19 
 
AgTfa, and AgOAc were tested obtaining best results when the 
trifluoroacetate salt was combined with triethylamine (10 mol%) 
as base (Table 4, entries 1-3). Other different bases such as 
DIPEA, DABCO, or DBU were essayed finding a very 
noticeable increment of the enantioselection with AgTfa/DABCO 
mixture (up to 50% ee) (Table 4, entries 4-7). Quinuclidine based 
alkaloids were next tested in a double chiral induction, but the 
results never overtook 40% ee (Table 4, entries 8-11). Also 
unfruitful were the transformations carried out with these silver 
salts in the absence of base. Poor enantioselection of cycloadduct 
19 (up to 32% ee) was isolated in moderate chemical yields (55-
65%). 
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Scheme 9. Reagents and conditions: i) (Sa)-Binap (10 mol%), AgI salt (10 
mol%), base (10 mol%), toluene, 20-25 ºC, 48 h.  
 
Table 4. Optimization of the reaction of imino ester 21 with 11. 
   Product 19 
 AgI salt Base  Yield (%)a,b ee (%)c 
1 AgSbF6 Et3N 55 32 
2 AgOAc Et3N 45 30 
3 AgTfa Et3N 55 35 
4 AgTfa DIPEA 80 30 
5 AgTfa DABCO 59 50 
6 AgSbF6 DABCO 50 30 
7 AgTfa DBU 63 24 
8 AgTfa Cinchonine 87 40 
9 AgTfa Cinchonidine 81 40 
10 AgTfa Quinine 71 45 
11 AgTfa Quinidine 77 -12  
a Isolated yield of the endo-product after flash chromatography.   
b The endo/exo ratio could not be determined from the crude product. 
c Determined by HPLC of the crude product employing chiral column (Daicel 
Chiralpak AD).  
 
Under the best reaction conditions described in Table 4 imino 
ester 22 was submitted to the cycloaddition with disulfone 11 
affording cycloadduct 20 in 60% chemical yield and a very poor 
enantioselectivity (12% ee) 
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Scheme 10. Reagents and conditions: i) (Sa)-Binap (10 mol%), AgTfa (10 
mol%), DABCO (10 mol%), toluene, 25 ºC, 48 h.  
 
In spite of the low enantioselections registered in the reaction 
performed between imino ester 3aa and acrylates, the 1,3-DC of 
the heterocyclic imino ester 23 and tert-butyl acrylate was 
attempted (Scheme 11 and Table 6). Such as it has been reported 
in previous works by our group, molecule 24 is the key 
intermediate in the elaboration of 2nd generation GSK inhibitors 
of the virus causing hepatitis C 25.9,21 AgClO4, AgTfa, and 
AgSbF6 were tested (Table 6), and unexpectedly the reactions 
afforded good chemical yields at 25 ºC, for 48 h and with high 
enantioselections, especially for the reaction carried out with 
silver perchlorate (88% ee) (Table 6, entry 1). The reaction 
needed a 10 mol% of both of the catalyst loading and 
triethylamine to occur. The lowering of the temperature, the use 
of different solvents from toluene, and several bases did not 
ameliorate the results described in Table 6.  
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Scheme 11. Reagents and conditions: i) (Sa)-Binap (10 mol%), AgX (10 
mol%), Et3N (10 mol%), toluene, 25 ºC, 48 h.  
 
Table 6. Synthesis of antiviral agent precursor 24. 
  Product 24 
Entry AgX Yield (%)a,b ee (%)c 
1 AgClO4 78 88 
2 AgTfa 75 88 
3 AgSbF6 79 72 
a Isolated yield of the endo-product after flash 
chromatography.   
b The endo/exo ratio was >98:2 (1H NMR). 
c Determined by HPLC of the crude product 
employing chiral column (Daicel Chiralpak AD).  
 
We can conclude once more that a minimum variation in structures 
of dipole-dipolaorphile or in the reaction parameters can origin a 
dramatic change in the final enantioselection of the chiral Binap-
silver(I) complexes when they catalyze enantioselective 1,3-dipolar 
cycloadditions between azomethine ylides and electrophilic alkenes. 
The importance of replacing perchlorate salts by other different 
anions is also desirable since the industrial point of view. Silver 
hexafluoroantimonate catalyze efficiently cycloadditions dealing 
with maleimides and 1,2-bis(phenylsulfonyl)ethylene obtaining best 
results when sterically hindered dipole precursors are employed, 
improving the publicated results using silver(I) perchlorate as co-
catalyst. Also noticeable are multicomponent transformations run in 
the presence of AgSbF6 whilst the analogous reaction, mediated by 
silver(I) perchlorate, completely failed. However, silver 
trifuoroacetate was much more effective, or as effective as silver(I) 
perchlorate, in the applications of this methodology into the 
synthesis of natural (crispine or harmicine precursors) or biologically 
attractive compounds (antiviral precursors). 
Experimental part 
1. General 
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 All reactions were carried out in the absence of light. Anhydrous 
solvents were freshly distilled under an argon atmosphere. 
Aldehydes were also distilled prior to use for the elaboration of the 
imino esters. Melting points were determined with a Reichert 
Thermovar hot plate apparatus and are uncorrected. Only the 
structurally most important peaks of the IR spectra (recorded on a 
Nicolet 510 P-FT) are listed. 1H NMR (300 MHz) and 13C NMR (75 
MHz) spectra were obtained on a Bruker AC-300 using CDCl3 as 
solvent and TMS as internal standard, unless otherwise stated. 
Optical rotations were measured on a Perkin Elmer 341 polarimeter. 
HPLC analyses were performed on a JASCO 2000-series equipped 
with a chiral column (detailed for each compound in the main text), 
using mixtures of n-hexane/isopropyl alcohol as mobile phase, at 25 
ºC. Low-resolution electron impact (EI) mass spectra were obtained 
at 70eV on a Shimadzu QP-5000 and high-resolution mass spectra 
were obtained on a Finnigan VG Platform. HRMS (EI) were 
recorded on a Finnigan MAT 95S. Microanalyses were performed on 
a Perkin Elmer 2400 and a Carlo Erba EA1108. Analytical TLC was 
performed on Schleicher & Schuell F1400/LS silica gel plates and 
the spots were visualized under UV light (λ=254 nm). For flash 
chromatography we employed Merck silica gel 60 (0.040-0.063 
mm). 
2. 1,3-Dipolar cycloaddition of imino esters 3, 9, 21, 22, or 23 and 
dipolarophiles. General procedure. 
A solution of the imino ester  (1 mmol) and dipolarophile (1 
mmol) in toluene (5 mL) was added to a suspension containing  (R)- 
or (S)-Binap (0.05 mmol, 31 mg) and AgX (0.05 mmol) in toluene (5 
mL). To the resulting suspension triethylamine (0.05 mmol, 7 µL) 
was added and the mixture stirred at room temperature and in the 
absence of the light for 16-48 h (see main text). The precipitate was 
filtered  and the complex was recovered. The organic filtrate was 
directly evaporated and the residue was purified by recrystallization 
or by flash chromatography yielding pure endo-cycloadducts. 
 
Methyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxooctahydro 
pyrrolo [3,4-c]pyrrole-1-carboxylate endo-5aa.5b 
Ethyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxooctahydro 
pyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ab.5b 
Isopropyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxoocta 
hydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ac.5b 
tert-Butyl (1S,3R,3aS,6aR)-5-methyl-3-phenyl-4,6-dioxoocta 
hydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ad.5b 
Methyl (1S,3R,3aS,6aR)-5-methyl-3-(2-naphthyl)-4,6-dioxoocta 
hydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ba.5a 
Methyl (1S,3R,3aS,6aR)-5-methyl-4,6-dioxo-3-o-tolyloctahydro 
pyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ca.5b 
Methyl (1S,3R,3aS,6aR)-3-(2-chlorophenyl)-5-methyl-4,6-dioxo 
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5da.5a 
Methyl (1S,3R,3aS,6aR)-5-methyl-3-(4-methylphenyl)-4,6-dioxo 
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ea.5a 
Methyl (1S,3R,3aS,6aR)-3-(4-chlorophenyl)-5-methyl-4,6-dioxo 
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5fa.5a 
Methyl (1S,3R,3aS,6aR)-3-(3-pyridyl)-5-methyl-4,6-dioxoocta 
hydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ga.22 
Methyl (1S,3R,3aS,6aR)-5-methyl-4,6-dioxo-3-(2-thienyl)octa 
hydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-5ha.5a 
Methyl (1S,3R,3aS,6aR)-5-ethyl-4,6-dioxo-3-phenyloctahydro 
pyrrolo[3,4-c]pyrrole-1-carboxylate endo-6.23 
Methyl (1S,3R,3aS,6aR)-4,6-dioxo-3,5-diphenyloctahydro 
pyrrolo[3,4-c]pyrrole-1-carboxylate endo-7. 
Methyl (1S,3R,3aS,6aR)-5-benzyl-4,6-dioxo-3-phenyloctahydro 
pyrrolo[3,4-c]pyrrole-1-carboxylate endo-8. Pale yellow oil; [α]D20 
= + 69.4º (c 1, CHCl3, 98% ee from HPLC); IR νmax  1740-1705, 
3260 cm-1; 1H NMR δH: 2.10 (s, 1H, NH), 3.33, 3.58 (2xdeform. d, J 
= 7.0, Hz, 2H, CH2Ph), 3,40 (d, J = 7,5 Hz, 1H, CCH), 3,58 (dd, J = 
9.1, and 7.6 Hz, 1H, CHCHCO2CH3), 3.76 (s, 3H, CO2Me), 3.58 (d, 
J = 7.1 Hz, 1H, CHCO2CH3), 4.25 (d, J  = 6.8 Hz, 1H, CHAr), 7.27-
7.48 (m, 10H, ArH); 13C RMN δC: 46.2 (CH2Ph), 47.1, 48.9 
(2xCHCON), 51.9 (CH3), 61.4, 66.2 (2xCHN), 128.1, 128.5, 125.9, 
140.5, 126.9, 128.6, 126.7, 136.5 (ArC), 176.4, 176.0, 171.6 (3xCO); 
MS (EI-GC) m/z: 364 (M++1, 2%), 273 (100), 91 (47), 68 (11); 
HRMS calculated for C21H20N2O4: 364.1423, found: 364.1430; 
HPLC (Chiralpak AS, 1 mL/min, n-hexane/i-PrOH: 20/80, λ 225 
nm), tRmaj = 10.5 min, tRmin = 26.7 min. 
Methyl (1S,3R,3aS,6aR)-1,5-dimethyl-4,6-dioxo-3-phenyloctahydro 
pyrrolo[3,4-c]pyrrole-1-carboxylate endo-10a.5b 
Methyl (1S,3R,3aS,6aR)-1-isobutyl-5-methyl-4,6-dioxo-3-(2-thienyl) 
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-10b.5b 
Methyl (1S,3R,3aS,6aR)-1-benzyl-5-methyl-4,6-dioxo-3-phenyl 
octahydropyrrolo[3,4-c]pyrrole-1-carboxylate endo-10c.5b 
Methyl (2R,3R,4R,5S)-5-phenyl-3,4-bis(phenylsulfonyl)pyrrolidine-
2-carboxylate endo-12aaa. Sticky oil, [α]D20 = +1.2º (c 1, CH2Cl2, 
90% ee from HPLC); IR (neat) νmax: 3311, 1753 cm-1; 1H RMN δH: 
2.80 (br. s, 1H, NH), 3.68 (s, 3H, CO2Me), 4.33 (m, 1H, 
PhCHCHSO2Ph), 4.41 (dd, J = 2.4, 6.3 Hz, 1H, NCCHSO2Ph), 4.47 
(dd, J = 2.4, 6.0 Hz, 1H, CHCO2Me), 4.64 (m, 1H, PhCHN), 7.28-
7.26 (m, 2H, ArH), 7.34-7.32 (m, 2H, ArH), 7.46-7.42 (m, 2H, ArH), 
7.61-7.52 (m, 3H, ArH), 7.72-7.65 (m, 6H, ArH); 13C RMN δC: 38.3 
(Me) 48.6 (CHCO2Me), 49.1, 52.7 (2xCHS), 56.0 (CHPh), 112.3, 
112.9, 113.2, 113.3, 113.7, 113.9 114.1, 114.2, 119.2, 121.9, 122.8, 
123.1 (ArC), 152.4 (CO); MS (EI) m/z (%): 485 (M+, <1%), 284 
(11), 203 (15), 202 (100), 170 (18), 144 (27), 143 (60), 115 (14), 77 
(14); HRMS calculated for C24H23NO6S2: 485.0967, found: 
485.0990; HPLC (Chiralpak IA, 1 mL/min, n-hexane/i-PrOH: 80/20, 
λ 224 nm), tRmaj = 50.23 min, tRmin = 30.92 min. 
Methyl (2R,3R,4R,5S)-5-(naphth-2-yl)-3,4-bis(phenylsulfonyl) 
pyrrolidine-2-carboxylate endo-12baa. Sticky oil, [α]D20 = +17.1º (c 
0.5; CH2Cl2, 92% ee from HPLC); IR (neat) νmax: 1741, 3340cm-1; 
1H RMN δH: 2.20 (br. s, 1H, NH), 3.69 (s, 3H, CO2Me); 4.38 (m, 
1H, ArCHCHSO2Ph), 4.45 (dd, J = 2.4, 6.4 Hz, 1H, NCCHSO2Ph), 
4.49 (dd, J = 2.4, 6.0 Hz, 1H, CHCO2Me), 4.79 (m, 1H, CHAr), 
7.39-7.35 (m, 2H, ArH), 7.56-7.45 (m, 6H, ArH), 7.72-7.60 (m, 7H, 
ArH), 7.81-7.77 (m, 2H, ArH); 13C RMN δC: 38.5 (Me), 48.6 
(CHCO2Me), 49.1, 52.7 (2xCHSO2), 55.9 (ArCH), 109.3, 111.2, 
111.3, 112.0, 112.4, 112.5, 112.9, 113.0, 113.3, 113.4, 113.5, 113.8, 
114.2, 114.3, 119.2, 120.0, 121.1, 121.3 (ArC), 152.5 (CO); MS (EI) 
m/z (%): 535 (M+, <1%), 394 (26), 392 (11), 391 (35), 359 (28), 268 
(21), 267 (19), 266 (17), 253 (19), 252 (100), 251 (31), 250 (13), 220 
(31), 219 (31), 194 (35), 193 (62), 192 (22), 191 (31), 190 (41), 167 
(15), 166 (11), 165 (47), 164 (13), 163 (15), 155 (11), 153 (11), 152 
(22), 142 (11), 127 (17), 125 (14), 78 (20), 77 (46), 51 (15); HRMS 
calculated for C28H25NO6S2: 535.1123; found: 535.1110; HPLC 
(Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 75/25, λ 227 nm), tRmaj 
= 57.01 min, tRmin = 51.97 min. 
Methyl (2R,3R,4R,5S)-2-methyl-5-(naphth-2-yl)-3,4-bis(phenyl 
sulfonyl)pyrrolidine-2-carboxylate endo-12bba: Colorless oil, [α]D 20 
= +5.2º (c  1; CH2Cl2, 24% ee from HPLC); IR (neat) νmax: 1748 
3341 cm-1; 1H RMN δH: 1.80 (s, 3H, CH3), 3.79 (s, 3H, CO2Me), 
3.46-3.43 (m, 1H, NH), 4.48 (d, J = 3.9 Hz, 1H, ArCHCHSO2Ph), 
4.61 (dd, J = 3.9, 7.2 Hz, 1H, NCCHSO2Ph), 4.83-4.77 (m, 1H, 
ArCH), 7.28-7.12 (m, 5H, ArH) , 7.51-7.43 (m, 5H, ArH),7.73-7.57 
(m, 6H, ArH), 7.90-7.87 (m, 1H, ArH); 13C RMN δC: 25.2 (CH3), 
39.2 (CO2Me), 49.0, 52.1 (2xCHSO2), 56.9 (ArCH), 73.5 (CMe), 
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111.7, 112.0, 112.5, 112.9, 113.0, 124.0, 126.3, 126.4, 127.5, 127.6, 
128.0, 128.2, 128.8, 129.0, 129.1, 129.4, 134.1, 134.4 (ArC), 171.0 
(CO); MS (EI) m/z (%): 549 (M+, < 1%), 408 (22), 348 (15), 267 
(20), 266 (100), 234 (31), 208 (39), 207 (91), 206 (27), 193 (19), 165 
(20), 77 (14). HRMS required for C29H27NO6S2: 549.1280; found: 
549.1301; HPLC (Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 
60/40, λ 227 nm), tRmaj = 18.21 min, tRmin = 39.37 min. 
Methyl (2R,3R,4R,5S)-3,4-bis(phenylsulfonyl)-5-(o-tolyl)pyrrolidine-
2-carboxylate endo-12caa): Colourless sticky oil, [α]D20 = +1.7º (c  
0.9; CH2Cl2, 18% ee from HPLC); IR (neat) νmax: 1749, 3341 cm-1; 
1H RMN δH: 2.42 (s, 3H, ArCH3); 2.90 (br. s, 1H, NH), 3.64 (s, 3H, 
CO2Me), 4.32 (s, 1H, ArCHCHSO2Ph), 4.48 (dd, J = 2.7, 6.2 Hz, 
1H,  NCCHSO2Ph), 4.65 (dd,  J = 2.7, 6.9 Hz, 1H, CHCO2Me), 4.97 
(s, 1H, ArCH), 7.25-7.16 (m, 2H, ArH), 7.41 (t, J = 7.6 Hz, 8.0 Hz, 
2H, ArH), 7.58-7.54 (m, 5H, ArH), 7.71-7.67 (m, 5H, ArH), 13C 
RMN δC: 37.4 (OMe), 44.3 (ArMe), 50.0 (CHCO2Me), 53.0, 55.5 
(2xCHSO2), 57.8 (ArCH), 110.9,  111.9, 113.1, 113.3, 114.2, 114.3, 
115.5, 119.1, 119.2, 120.8, 122.0, 122.1, 123.1, 124.6, (ArC),152.3 
(CO); MS (EI) m/z (%): 499 (M+, < 1%), 298 (10), 217 (16), 216 
(100), 184 (18), 158 (29), 157 (49), 156 (20), 143 (12), 129 (11), 77 
(23); HRMS calculated for C25H25NO6S2: 499.1123; found: 
499.1134; HPLC (Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 
80/20, λ 227 nm), tRmaj = 35.89 min, tRmin = 43.91 min. 
Methyl (2R,3R,4R,5S)-3,4-bis(phenylsulfonyl)-5-(p-tolyl)pyrrolidine-
2-carboxylate (12daa): Colourless sticky oil, [α]D20 = +2.3º (c 1; 
CH2Cl2, 88% ee from HPLC); IR (neat) νmax: 1747, 3341 cm-1; 1H 
RMN δH: 2.30 (s, 3H, ArCH3); 2.20 (br. s, 1H, NH), 3.66 (s, 3H, 
CO2Me), 4.31-4.27 (m, 1H, ArCHCHSO2Ph), 4.35 (dd, J = 2.4, 6.4 
Hz, 1H, NCCHSO2Ph), 4.41 (dd, J = 2.4, 6.0 Hz, 1H, CHCO2Me), 
4.61-4.57 (m, 1H, ArCH), 7.06 (d, J = 8.1 Hz, 1H, ArH), 7.20 (d, J = 
8.1 Hz, 1H, ArH), 7.54-7.40 (m, 6H, ArH), 7.64-7.57 (m, 2H, ArH), 
7.70-7.66 (m, 4H, ArH), 13C RMN δC: 21.2 (CH3Ar), 53.6 (OMe), 
63.5, 64.2 (2xCHSO2), 67.9 (CHCO2Me), 71.2 (ArCH), 127.3, 
128.5, 128.6, 129.1, 129.3, 129.4, 129.5, 134.3, 135.0, 138.2, 138.3 
(ArC), 167.6 (CO); MS (EI) m/z (%): 499 (M+, < 1%), 358 (24), 217 
(15), 216 (100), 184 (22), 158 (22), 157 (48), 156 (14), 77 (15); 
HRMS required for C25H25NO6S2: 499.1123; found: 499.1122; 
HPLC (Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 75/25, λ 220 
nm), tRmaj = 50.08 min, tRmin = 26.11 min. 
Methyl (2R,3R,4R,5S)-5-(4-methoxyphenyl)-3,4-bis(phenylsulfonyl) 
pyrrolidine-2-carboxylate endo-12eaa: Colourless sticky oil, [α]D20 
= - 4.5º (c 1; CH2Cl2, 38% ee from HPLC); IR (neat) νmax: 1747, 
3341 cm-1; 1H RMN δH: 2.70 (br. s, 1H, NH), 3.68, 3.80 (2xs, 6H, 
CO2Me); 4.31 (s, 1H, ArCHCHSO2Ph), 4.35 (dd, J = 2.4, 6.4 Hz, 
1H, NCCHSO2Ph), 4.44 (dd, J = 2.4, 6.0 Hz, 1H, CHCO2Me), 4.61 
(s, 1H, ArCH), 7.29-7.24 (m, 2H, ArH), 7.47-7.43 (m, 2H, ArH), 
7.63-7.52 (m, 5H, ArH), 7.72-7.66 (m, 5H, ArH); 13C RMN δC: 37.4, 
40.1 (2xOMe), 45.3 (CHCO2Me), 49.0, 52.7 (2xCHSO2), 56.0 
(ArCH), 99.0, 113.4, 113.5, 114.2, 114.3, 119.2, 119.5, 120.8, 121.9, 
122.2, 123.0, 144.4 (ArC), 152.4 (CO); MS (EI) m/z (%): 515 (M+, < 
1%), 375 (17), 374 (77), 233 (17), 232 (100), 231 (14), 200 (31), 199 
(16), 174 (27), 173 (46), 172 (11), 159 (11), 158 (23), 130 (11), 78 
(10), 77 (29); HRMS required for C25H25NO7S2: 515.1072; found: 
515.1082; HPLC (Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 
70/30, λ 230 nm), tRmaj = 38.85 min, tRmin = 43.96 min. 
Methyl (2R,3R,4R,5S)-5-(4-chlorophenyl)-3,4-bis(phenylsulfonyl) 
pyrrolidine-2-carboxylate endo-12faa: Colourless viscous oil, [α]D20 
= +91.6º (c 1; CH2Cl2, 45% ee from HPLC); IR (neat) νmax: 1750, 
3341 cm-1; 1H RMN δH: 2.40 (br. s, 1H, NH), 3.67 (s, 3H, CO2Me); 
4.30 (dd, J = 2.3, 6.3 Hz, 1H, ArCHCHSO2Ph), 4.34 (m, 1H, 
NCCHSO2Ph), 4.38 (dd, J = 2.3, 5.9 Hz, 1H, CHCO2Me), 4.66-4.61 
(m, 1H, ArCH), 7.30-7.21 (m, 3H, ArH), 7.53-7.43 (m, 4H, ArH), 
7.71-7.59 (m, 7H, ArH); 13C RMN δC: 37.5 (Me); 45.2 (CHCO2Me), 
48.9, 52.6 (2xCHSO2), 55.9 (ArCH), 113.2, 113.5, 113.8, 113.9, 
114.2, 114.3, 114.5, 114.8, 119.2, 119.5, 121.7, 123.0 (ArC), 152.3 
(CO); MS (EI) m/z (%): 519 (M+, < 1%), 238 (32), 237 (17), 236 
(100), 235 (12), 204 (19), 203 (15), 179 (17), 178 (19), 177 (48), 143 
(21), 140 (14), 125 (16), 115 (13), 77 (29), 152 (13); HRMS required 
for C24H22ClNO6S2: 519.0577; found: 519.0585; HPLC (Chiralpak 
AD, 1 mL/min, n-hexane/i-PrOH: 70/30, λ 220 nm), tRmaj = 41.08 
min, tRmin = 34.69 min. 
Isopropyl (2R,3R,4R,5S)-5-(4-chlorophenyl)-3,4-bis(phenylsulfonyl) 
pyrrolidine-2-carboxylate endo-12fab: Colourless needles, mp 178 
ºC (CH2Cl2/n-hexane); [α]D20 = +37.0º (c 0.7, CHCl3, 40% ee from 
HPLC); IR (KBr) νmax: 1735, 3328 cm-1; 1H RMN δH: 1,33, 1.41 
[2xd, J = 6.2 Hz, 6H, CO2CH(CH3)2], 2.42 (br. s, 1H, NH), 4.30 
(dd, J = 2.3, 6.3 Hz, 1H, ArCHCHSO2Ph), 4.34 (m, 1H, 
NCCHSO2Ph), 4.38 (dd, J = 2.3, 5.9 Hz, 1H, CHCO2Me), 4.66-4.61 
(m, 1H, ArCH), 5.20 (m, 1H, CHMe2); 7.21-7.81 (m, 7Hz, 14H, 
ArH); 13C RMN δC: 21.6, 21.9 [CH(CH3)2], 45.2 (CHCO2), 47.5, 
48.9 (2xCHSO2), 55.9 (ArCH), 62.0 [CH(CH3)2], 113.2, 113.5, 
113.7, 113.9, 114.0, 114.1, 114.5, 114.6, 119.4, 119.5, 121.7, 123.0 
(ArC), 152.3 (CO); MS (EI) m/z (%): 513 (M+, 2%), 229 (100), 140 
(14); HRMS calculated for C17H20N2O4: 513.11280; found: 
513,11289; Microanalysis for C26H27NO6 S2: C, 60.8; H, 5.3; N, 
2.8%, found: C, 60.5; H, 5.3; N, 2.5; HPLC (Chiralpak OD-H, 1 
mL/min, n-hexane/i-PrOH: 80/20, λ 215 nm), tRmaj = 20.5 min, tRmin 
= 38.4 min. 
Methyl (2R,3R,4R,5S)-3,4-bis(phenylsulfonyl)-5-(pyrid-3-yl) 
pyrrolidine-2-carboxylate endo-12gaa: Colourless sticky oil, [α]D20 
= – 63.9º (c 1.2; CH2Cl2, 92% ee from HPLC); IR (neat) νmax: 1753, 
3310 cm-1; 1H RMN δH: 2.25 (br. s, 1H, NH), 3.68 (s, 3H, Me); 4.33 
(dd, J = 2.3, 6.4 Hz, 1H, ArCHCHSO2Ph), 4.35 (s, 1H, 
NCCHSO2Ph), 4.43 (dd, J = 2.3, 5.9 Hz, 1H, CHCO2Me), 4.66 (d, J 
= 6.4 Hz, 1H, ArCH), 7.46 (t, J = 7.7 Hz, 8.0 Hz, 2H, ArH), 7.53 (t, 
J = 7.4 Hz, 2H, ArH), 7.61-7.65 (m, 3H, ArH), 7.70 (t, J = 7.4 Hz, 
5H, ArH), 8.36 (s, 1H, ArH), 8.52 (s, 1H, ArH); 13C RMN δC: 34.6, 
37.5 (CHCO2Me), 48.9, 52.4 (2xCHSO2), 55.7 (ArCH), 108.7, 
113.3, 113.4, 114.3, 114.6, 119.3, 119.6, 119.8, 120.1, 121.5, 122.5 
134.0, 134.7 (ArC), 152.3 (CO); MS (EI) m/z (%): 289 (M+, 18%); 
HRMS calculated for C23H22N2O6S2: 289.1062; found: 289.1064; 
HPLC (Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 50/50, λ 222 
nm), tRmaj = 15.05 min, tRmin = 7.91 min. 
Methyl (2R,3R,4R,5S)-2-isobutyl-3,4-bis(phenylsulfonyl)-5-(thien-2-
yl)pyrrolidine-2-carboxylate endo-12hca: Pale yellow oil, [α]D 20 = 
7.1º (c 1; CH2Cl2, 70% ee from HPLC); IR (neat) νmax: 1779, 3338 
cm-1; H RMN δH: 0.88 [d, J = 6.7 Hz, 3H, CH(CH3)2], 1.08 [d, J = 
6.4 Hz, 3H, CH(CH3)2], 1.84-1.74 [m, 1H, CH(CH3)2], 1.98 [dd, J = 
6.4, 14.6 Hz, 1H, CH2CH(CH3)2], 2.22 [dd, J = 5.7 Hz, 14.6 Hz, 
1H, CH2CH(CH3)2], 3.10 (br. s, 1H, NH), 3.82 (s, 3H, CO2Me), 
4.40 (d, J = 3.9 Hz, 1H, ArCHCHSO2Ph), 4.46 (dd, J = 3.9 Hz, 7.2 
Hz, 1H, NCCHSO2Ph), 4.88 (m, 1H, ArCH), 7.21-7.13 (m, 2H, 
ArH), 7.36-7.26 (m, 4H, ArH), 7.54-7.45 (m, 4H, ArH), 7.65-7.61 
(m, 1H, ArH), 7.76-7.23 (m, 1H, ArH), 7.90 (d, J = 7.3 Hz, 1H, 
ArH); 13C RMN δC: 24.4, 24.6 [CH(CH3)2], 28.4 [CH(CH3)2], 37.7 
(CH2), 39.5, 43.7,  57.8 (OMe and 2xCHSO2), 58.4, 58.9 (CCO, 
NCH), 110.2, 110.5, 111.1, 111.7, 113.0, 114.0, 114.2, 118.9, 119.2, 
123.2, 123.3, 125.7, (ArC),  155.2 (CO). MS (EI) m/z (%): 547 (M+, 
< 1%), 488 (13), 406 (13), 348 (28), 346 (22), 317 (12), 316 (66), 
265 (16), 264 (100), 232 (22), 208 (26), 207 (25), 206 (26), 205 (57), 
176 (26), 175 (12), 162 (43), 150 (13), 149 (30), 121 (14), 77 (20); 
HRMS calculated for C26H29NO6S3: 547.1157; found: 547.1151. 
HPLC (Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 70/30, λ 233 
nm), tRmaj = 19.67 min, tRmin = 23.43 min.  
Methyl (2R,3R,4R,5S)-2-isobutyl-3,4-bis(phenylsulfonyl)-5-(thiazol-
2-yl)pyrrolidine-2-carboxylate endo-12ica: Sticky oil, [α]D 20 = +4.1º 
(c 1; CH2Cl2, 10% ee from HPLC); IR (neat) νmax: 1735, 3328 cm-1.  
1H RMN δH: 0.87, 1.07 [2xd, J = 6.7 Hz, 6H, CH(CH3)2], 1.86-1.73 
[m, 1H, CH(CH3)2], 1.98 (dd, J = 6.4 Hz, 14.6 Hz, 1H, CH2), 2.22 
(dd, J = 5.7 Hz, 14.6 Hz, 1H, CH2), 3.79 (s, 3H, OMe), 4.40 (d, J = 
4.1 Hz, 1H, ArCHCHSO2Ph),  4.97 (dd, J = 7.1 Hz, 12.2 Hz, 1H, 
NCCHSO2Ph), 5.11 (dd, J = 4.1 Hz, 7.1 Hz, 1H, ArCH), 7.26-7.19 
(m, 3H, ArH), 7.38-7.33 (m, 2H, ArH), 7.62-7.50 (m, 5H, ArH), 
7.74-7.68 (m, 1H, ArH), 7.88-7.85 (m, 2H, ArH); 13C RMN δC: 24.5, 
24.7 [CH(CH3)2], 28.0 [CH(CH3)2], 37.9 (CH2), 39.9, 43.9,  57.2 
(OMe and 2xCHSO2), 58.4, 58.4 (CCO, NCH), 110.2, 110.5, 111.7, 
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113.4, 114.4, 114.2, 118.4, 119.2, 123.1, 123.3, 125.9, (ArC),  155.8 
(CO); MS  (EI) m/z (%): 548 (M+, < 1%), 491 (26), 489 (19), 407 
(13), 351 (13), 347 (28), 317 (53), 266 (15), 265 (87), 233 (50), 221 
(12), 209 (35), 208 (71), 207 (52), 206 (100), 205 (10), 178 (11), 177 
(79), 176 (13), 164 (13), 163 (65), 151 (19); 150 (17), 141 (11), 125 
(16), 123 (17), 122 (13), 94 (10), 86 (10), 80 (12), 78 (13), 77 (44), 
59 (11); HRMS calculated for C25H28N2O6S2: 548.1109; found: 
548.1118. HPLC (Chiralpak AD, 1 mL/min, n-hexane/i-PrOH: 
70/30, λ 220 nm), tRmaj = 21.63 min, tRmin = 12.69 min.  
3. Multicomponent 1,3-Dipolar cycloaddition of glycine methyl 
ester hydrochloride. General procedure. 
To a suspension containing  (R)- or (S)-Binap (0.05 mmol, 31 mg) 
and AgSbF6 (17 mg, 0.05 mmol) in toluene (3 mL), triethylamine 
(6.6 µL, 0.05 mmol), the corresponding dipolarophile (1 mmol) and 
glycine methyl ester hydrochloride (126 mg, 1 mmol) were added in 
this order at 25 ºC. The reaction mixture was then stirred at the same 
temperature 16 or 48h (see Scheme 6). The solvent was evaprated 
under vacuo and the residue was purified by flash chromatography 
yielding products endo-5aa or endo-12gaa. 
4. Synthesis of pyrrolidine 16. 
To a solution of methyl (2R, 3S, 4S, 5S)-5-phenyl-3,4-
bis(phenylsulfonyl) pyrrolidine-2-carboxylate endo-12aaa, (22.0 mg, 
0.04 mmol), in a 3:1 mixture of MeOH/THF (3ml), 10% Na(Hg) 
(69.3 mg) and Na2HPO4 (22.4 mg, 0.16 mmol) were sequentially 
added at 0 ºC. After stirring for 1h at room temperature, ethyl acetate 
(10 ml) was added, and the resulting suspension was filtered and 
washed with water (2x5 ml). The aqueous phase was extracted with 
ethyl acetate (2x5 ml) and the combined organic phases were washed 
with brine (5 ml), dried and concentrated. The residue (7:5 mixture 
of 14 and 15) was next dissolved in methanol (3mL) and Pt/C (10%) 
(30 mg) was added. The reaction was stirred for 48h under an 
hydrogen atmosphere (1 atm) at 25 ºC and the final mixture filtered 
over a celite pad. The remaining solution was evaporated under 
vacuo and the residue was purified by flash chromatography yielding 
product 16a in 47% overall yield. 
Methyl 5-phenylpyrrolidine-2-carboxylate 16a. 
5. Synthesis of imine 21. 
To a solution of 3,4-dimethoxyphenethyl alcohol (3.0 g, 16.6 
mmol) in pyridine (4 ml) Ac2O (1.6 ml, 16.6 mmol), DMAP (0.040 
g, 0.33 mmol) and Et3N (2.35 ml, 16.6 mmol) were added in this 
order. The mixture was stirred for 4h. Water (5 mL) and ethyl acetate 
(3 x 6 ml) were added, and the resulting organic layers were washed 
with brine. The crude product was employed in the next step without 
purification. This aldehyde [2-(2-acetoxyethyl)-4,5-
dimethoxybenzaldehyde] (252 mg, 1 mmol), glycine methyl ester 
hydrochloride (126 mg, 1 mmol), Et3N (1.1 mmol) and MgSO4 (100 
mg) were suspended in chloroform and the mixture refluxed during 
16 h. The mixture was then filtered and the resulting organic phase 
washed with water (2x5 mL). The organic layer was dried (MgSO4) 
and evaporated under vacuo obtaining imine 21 in 96% crude pure 
yield. 
Methyl (E)-2-{[(2-(2-acetoxyethyl)-4,5-dimethoxybenzylidene] 
amino}acetate 21: Pale yellow oil; IR (neat) υmax: 1741, 1731, 1634 
cm-1; 1H-RMN δH: 1.96 (s, 3H, CH3CO2), 3.05 (t, J = 7.3 Hz, 2H, 
AcOCH2), 3.61 (s, 3H, CO2CH3), 3.84, 3.85 (2xs, 6H, 2xOCH3), 
4.16 (t, J = 7.3 Hz, 2H, PhCH2),  4.36 (s, 2H, NCH2), 6.61 (s, 1H, 
ArH), 7.46 (s, 1H, ArH), 8.48 (s, 1H, NCH); 13C-RMN δC: 20.9 
(CH3CO), 31.3 (CH2Ar), 52.0, 55.8, 56.0 (3xOMe), 62.1, 65.0 
(CH2CO, CH2O), 109.7, 112.8, 126.5, 131.3, 148.1, 151.4 (ArC), 
162.9 (CN), 170.7, 170.9 (2xCO); MS (EI) m/z (%): 323.2 (M+, 5%), 
264 (21), 263 (26), 262 (100), 190 (13), 176 (14), 175 (59); HRMS 
calculated for C16H21NO6: 323.1369; found: 323.1361. 
6. Synthesis of cycloadduct 19. 
A suspension of silver(I) salt (0.01 mmol), and (S)-Binap (6 mg, 
0.01 mmol) in toluene was stirred at 25 ºC for 30 min avoiding the 
light exposure. Then, imine 21 (32 mg, 0.1 mmol), 1,2-
bis(phenylsulfonyl)ethylene (31 mg, 0.1 mmol) and the 
corresponding base (0.01 mmol, see Table 4) were added in this 
order. The reaction was stirred 48 h at 25 ºC and water (5 mL) and 
the aqueous phase extracted with ethyl acetate (2x5 mL). The 
organic layer was dried (MgSO4) and evaporated under vacuo 
obtaining cycloadduct 19.  
Methyl (2R,3S,4S,5S)-5-[2-(2-acetoxyethyl)-4,5-dimethoxyphenyl]-
3,4-bis(phenylsulfonyl)pyrrolidine-2-carboxylate 19: Colourless 
needles, mp 92-94 ºC (n-hexane/ethyl acetate); [α]D20 =  −25.3º (c  1, 
CHCl3, 50% ee from HPLC); IR (KBr) υmax: 1148, 1309, 1738, 
3306 cm-1; 1H-RMN δH: 2.05 (s, 3H, CH3CO2), 2.30 (br. s, 1H, 
NH), 2.85, 3.18 (2m, 2H, PhCH2), 3.60 (s, 3H, CO2CH3), 3.88, 3.91 
(2s, 6H, 2xOCH3), 4.25-4.28 (m, 4H, AcOCH2, CHS, CHCO2Me), 
4.60 (dd, J = 6.3, 1.9 Hz, 1H, CHS), 5.04 (d, J = 6.3 Hz, 1H, PhCH), 
6.63 (s, 1H, ArH), 7.31 (s, 1H, ArH), 7.43-7.74 (m, 10H, ArH); 13C-
RMN δC: 21.0 (CH3CO), 31.9 (CH2Ar), 45.6, 49.9, 52.4, 55.9, 56.1, 
58.6 (CHCO2Me 3xOMe and 2 CHS), 64.4, 64.8 (CH2CO, CH2O), 
68.5 (ArCH), 109.8, 112.8, 128.1, 128.4, 129.1, 129.3, 129.5, 134.2, 
135.5, 137.3, 137.4, 137.5, 138.3, 148.7 (ArC), 167.4, 171.0 (2xCO); 
MS (EI) m/z (%): 631.1 (M+, 0.1%), 348 (16), 347 (79), 272 (13), 
256 (17), 255 (25), 254 (21), 229 (17), 228 (100), 227 (55), 215 (17), 
214 (11), 213 (11), 212 (16), 200 (14), 197 (12), 196 (13), 184 (13); 
Microanalysis for C30H33NO10 S2: C, 57.0; H, 5.3; N, 2.2%, found: 
C, 57.3; H, 5.3; N, 2.5; HPLC (Chiralpak AD, 1mL/min, n-hexane/i-
PrOH: 70/30, λ 217nm), tRmaj = 28.20 min, tRmin = 21.53. 
7. Synthesis of imine 22.24 
To a cooled solution (0 ºC) of tryptophol (0.5 g, 3.1 mmol) and  
imidazole (0.46 g, 6.8 mmol) in DMF (3 mL) TBDMCl (0.51 g, 3.4 
mmol) was added, and the reaction mixture stirred for 16 h at 26 ºC. 
Ethyl acetate was added (10 mL) and the organic phase was washed 
with brine (3x4 mL). The organic phase was dried with MgSO4 and 
evaporated under vacuo and the residue purified by flash 
chromatography obtaining the silyl-protected derivative (0.84 g, 99 
%). A solution of it (0.84 g, 3.1 mmol) in anhydrous DMF (3 mL) 
was slowly added, at 0 ºC, to a suspension of 60% NaH (0.19 g, 9.5 
mmol) in anhydrous DMF (2 mL) and stirring continued at 25 ºC 
during 30 min. Then, PhSO2Cl (0.53 ml, 4 mmol) was added in one 
portion and the reaction was maintained at the same temperature for 
another 19 h. A saturated solution of ammonium chloride was poured 
out (10 mL) and the aqueous phase was extracted with diethyl ether 
(3x15 mL) and the combined organic phases were dried with MgSO4 
and evaporated under vacuo and the residue purified by flash 
chromatography obtaining the N-phenylsulfonyl derivative (0.79 g, 
81%). The final formylation was achieved by preparing a solution of 
the last compound (0.79 g, 1.90 mmol) in anhydrous THF (2 mL), 
which was cooled to -78 ºC and treated with 1.6 M solution of BuLi 
in hexanes (2.14 mL). After 2 h, the temperature was slowly 
increased to get 25 ºC and immediately cooled to -78 ºC. At that time 
DMF (0.77 ml, 1mmol) was added and the temperature again was 
allowed to rise to 25 ºC. A saturated solution of ammonium chloride 
was poured out (10 mL) and the aqueous phase was extracted with 
ethyl acetate (3x15 mL) and the combined organic phases were dried 
with MgSO4 and evaporated under vacuo and the residue purified by 
flash chromatography obtaining the desired aldehyde (0.63 g, 
75%).24b 
The imine 22 was prepared in 95% pure crude yield such as it was 
described for 21 (see above). 
(E)-Methyl 2-{[3-(2-[(tert-butyldimethylsilyloxy)ethyl]-1-(phenyl 
sulfonyl)-1H-indol-2-yl]methylene}aminoacetate 22: Orange sticky 
oil; IR (neat) υmax: 1747, 1631, 1371, 1170 cm-1; 1H-RMN δH: 
−0.17, 0.02 (2xs, 6H, 2xSiCH3), 0.87 [s, 9H, SiC(CH3)3],  2.88 (t, J 
= 6.7 Hz, 2H, CCH2), 3.31 (t, J = 6.7 Hz, 2H, OCH2), 3.81 (s, 3H, 
CO2CH3), 4.53 (s, 2H, NCH2), 7.41-8.00 (m, 9H, ArCH), 8.84 (s, 
1H, NCH); 13C-RMN δC: −2.8, −2.6, 18.2, 25.8, 28.5, 52.0, 62.5, 
63.2, 113.6, 115.3, 119.5, 120.3, 121.3, 123.0, 124.1, 124.5, 126.6, 
128.9, 129.1, 133.5, 158.6, 170.9; MS (EI) m/z (%): 514 (M+, 1%), 
359 (16), 358 (59), 233 (11), 217 (11), 216 (51), 200 (16), 199 (100). 
HRMS calculated for C26H34N2O5SSi: 514.1958; found: 514.1967. 
8. Synthesis of cycloadduct 20. 
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A suspension of silver(I) trifluoroacetate (3 mg, 0.01 mmol), and 
(S)-Binap (6 mg, 0.01 mmol) in toluene was stirred at 25 ºC for 30 
min avoiding the light exposure. Then, imine 22 (51 mg, 0.1 mmol), 
1,2-bis(phenylsulfonyl)ethylene (31 mg, 0.1 mmol) and DABCO 
corresponding base (2 mg, 0.01 mmol) were added in this order. The 
reaction was stirred 48 h at 25 ºC and water (5 mL) and the aqueous 
phase extracted with ethyl acetate (2x5 mL). The organic layer was 
dried (MgSO4) and evaporated under vacuo obtaining cycloadduct 
20.  
Methyl (2R,3R,4R,5S)- 5-{3-[2-((tert-butyldimethylsilyl)oxy)ethyl]-1-
(phenylsulfonyl)-1H-indol-2-yl}-3,4-bis(phenylsulfonyl)pyrrolidine-
2-carboxylate 20: Colourless needles, mp 155 ºC (n-hexane/ethyl 
acetate); [α]D20 = −4.5º (c 1; CHCl3, 12% ee from HPLC); IR (KBr) 
υmax: 1142, 1309, 1765, 3286 cm-1; 1H-RMN δH: −0.137, −0.04 (2xs, 
6H, 2xSiCH3), 0.79 [s, 9H, SiC(CH3)3], 2.81 (t, J = 6.6 Hz, 2H, 
OTBDMSCH2), 3.02 (td, J = 6.6, 1.9 Hz, 2H, CCH2), 3.76-3.79 (m, 
5H, CO2CH3, SCH, CHCO2CH3), 4.26 (d, J = 7.1 Hz, 1H, NCH2), 
4.87 (dd, J = 7.1, 4.7 Hz, 1H, CHN), 5.40 (s, 1H, NH), 7.07-8.01 (m, 
19H, ArCH); 13C-RMN δC: −5.5, −5.3, 18.0, 29.9, 30.0, 30.6, 48.4, 
51.9, 52.5, 62.5, 64.1, 108.7, 115.8, 115.9, 116.8, 116.9, 117.6, 
125.6, 125.7, 126.9, 127.0, 128.00, 128.46, 128.73, 129.13, 129.86, 
133.59, 134.09, 134.92, 136.96, 140.37, 171.5; MS (ESI) m/z (%): 
822 (M+, 2%). Microanalysis for C40H46N2O9 S3Si: C, 58.4; H, 5.6; 
N, 3.4%, found: C, 58.3; H, 5.3; N, 3.5; HPLC (Chiralpak OD-H, 1 
mL/min, n-hexane/i-PrOH: 93/7, λ 222nm), tRmaj = 24.5 min, tRmin = 
27.8 min. 
9. Synthesis of the antiviral precursor 24.25 
Compound 24  was prepared according to the procedure described 
before (see section 2). 
tert-Butyl methyl (2S,4S,5R)-2-isobutyl-5-(thiazol-2-yl)pyrrolidine-
2,4-dicarboxylate 24: [α]D 20 = +38º (c 1, CH2Cl2, 99% ee by HPLC) 
Lit. [α]D 20 = + 43º  (c 1, CH2Cl2, 99% ee by HPLC). 
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